Weilheim, Germany

Michael Rottmann

This inventor holds 1 USPTO granted patent. Top assignee: Roche Diagnostics Gmbh. Active years: 2003.


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Rottmann: Innovator in Cytokeratin Detection

Introduction

Michael Rottmann is a notable inventor based in Weilheim, Germany. He has made significant contributions to the field of medical diagnostics, particularly in the detection of cytokeratin. His work has implications for various medical applications, enhancing the accuracy and reliability of diagnostic methods.

Latest Patents

Rottmann holds a patent for the "Stabilization of calibrators containing cytokeratin." This invention focuses on calibrators or calibration solutions that utilize a human serum matrix. These solutions are essential for detecting cytokeratin, a critical protein in various medical conditions. The patent outlines a process for producing these calibrators, methods for stabilizing cytokeratin, and an immunological method for detecting cytokeratin in samples.

Career Highlights

Michael Rottmann is associated with Roche Diagnostics GmbH, a leading company in the field of medical diagnostics. His work at Roche has allowed him to contribute to innovative solutions that improve diagnostic accuracy. Rottmann's expertise in the field has positioned him as a valuable asset to the company and the medical community.

Collaborations

Rottmann has collaborated with notable colleagues, including Gunter Pappert and Norbert Franken. These collaborations have fostered an environment of innovation and have led to advancements in diagnostic technologies.

Conclusion

Michael Rottmann's contributions to the field of cytokeratin detection exemplify the impact of innovation in medical diagnostics. His patent and work at Roche Diagnostics GmbH highlight the importance of research and collaboration in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…